Phase 4 N=88 Optimizing Body Composition for Function in Older Adults
Obesity · Overweight With Indications for Weight Loss
Primary: Appendicular Non-bone Lean Mass — -2.53; -2.49; -2.04; -1.45 kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=44 The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension
High Blood Pressure
Primary: Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks — 2.739; 2.679; 1.963; 2.221 mL/100 mL/min
Phase 3 N=100 Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries
Encephalitis
Primary: Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs up to Day 56 After the First Vaccination — 33.3; 20.7; 3.4 percentage of participants
Phase 1 N=16 A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers
Epilepsy
Primary: Number of Adverse Events Reported — 6; 6; 1; 5 Number of adverse events reported
N/A N=177 Obesity and the Initiation of Knee Osteoarthritis
Obesity
Primary: Gait Knee Adduction Moment — 3.14; 2.39 percent body weight (N)*height (m)
Phase 1 N=14 Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
Partial Epilepsy
Primary: Cmax - Maximum Plasma Concentration in Plasma and Cerebral Spinal Fluid — 23932; 16162; 886; 4039 ng/mL
N/A N=300 Multi-Site Evaluation of Progressive Tinnitus Management
Tinnitus
Primary: Tinnitus Functional Index Change Score — -5.71; .8 units on a scale
Phase 3 N=618 Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Multiple Sclerosis
Primary: Core Treatment Period: Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) — 14.3; 8.7; 9.0; 26.0 percent probability — p=0.0087
N/A N=80 Comparison of Clinical Performance of the Guardian Laryngeal Mask With LMA Proseal
Efficacy of Oropharyngeal Seal Pressure
Primary: Oropharyngeal Seal Pressure — 32.36; 29.41 cmH2O — p=0.04
Phase 3 N=110 A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
Psoriasis
Primary: The Percentage of Participants Achieving a Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12 — 5.4; 67.6; 69.4 Percentage of…
Phase 2 N=68 Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma
Lymphoma
Primary: Overall Response Rate as Assessed According to the"Revised Response Criteria for Malignant Lymphoma" (Cheson 2007). — 5; 2; 7; 1 Participants
Phase 4 N=256 Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan
Hypertension · Chronic Kidney Disease · Microalbuminuria
Primary: ∆Albuminuria by 24-hour Urine Protein Excretion — 483.5; 569.9; 487.3; 417.4 mg/day — p=0.006
Phase 3 N=198 Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006)
Spondylitis, Ankylosing
Primary: Percentage of Participants Achieving an Assessment in Ankylosing Spondylitis (ASAS) 20 Response at Week 16 — 71.1; 40.0 Percentage of Participants — p=<0.0001
Phase 2 N=50 Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis
Non Alcoholic Steatohepatitis
Primary: Change in Liver Fat as Measured by MRI-PDFF — 15.0; 18.5; 11.6; 16.4 percentage of total fat
Phase 2 N=72 Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival at 2 Years — 36.60 percentage of participants